1,152 material Form 8-K filings that 918 companies we cover made with the SEC in October 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Interface reported third-quarter 2025 GAAP diluted earnings per share of $0.78, up 62.5% year over year, and adjusted diluted EPS of $0.61, up 27.1%. The company raised its full-year 2025 net sales outlook to $1.375 billion to $1.390 billion, from $1.370 billion to $1.390 billion, and its adjusted gross profit margin outlook to 38.5% from 37.7%. Both headline results and guidance moved higher for shareholders.
Q3 2025 net sales were $364.5 million, up 5.9% year over year and up 4.2% on a currency-neutral basis.
GAAP net income for the quarter was $46.1 million, up 62.2%, and diluted EPS was $0.78 versus $0.48 a year earlier.
Full-year 2025 net sales outlook raised to $1.375 billion to $1.390 billion; adjusted gross profit margin outlook raised to 38.5% of net sales.
Cash rose to $187.4 million at September 28, 2025, from $99.2 million at December 29, 2024, and net debt fell to $120.4 million.
Healthcare Realty reported third-quarter 2025 Normalized FFO of $0.41 per share, up from $0.39 a year earlier, and a GAAP net loss of $0.17 per share, narrower than the $0.26 loss in the prior-year quarter. The company raised its 2025 Normalized FFO per share guidance to $1.59-$1.61 and same store cash NOI growth guidance to 4.00%-4.75%, while third-quarter revenue of $297.8 million was below the $315.4 million reported a year earlier.
Normalized FFO per share was $0.41 in Q3 2025 versus $0.39 in Q3 2024; NAREIT FFO was $0.34 versus $0.21.
GAAP net loss attributable to common stockholders was $57.7 million ($0.17 per share) versus $93.0 million ($0.26 per share) a year earlier.
Total revenues were $297.8 million versus $315.4 million in Q3 2024.
2025 guidance: Normalized FFO per share raised to $1.59-$1.61 from $1.57-$1.61; same store cash NOI growth raised to 4.00%-4.75% from 3.25%-4.00%. The board approved a $0.24 per share dividend payable November 21, 2025.
VICI Properties reported third-quarter 2025 results with total revenues up 4.4% year-over-year to $1.0 billion and AFFO attributable to common stockholders up 7.4% to $637.6 million. The company raised the low end of its full-year 2025 AFFO guidance to between $2,510 million and $2,520 million, or $2.36 to $2.37 per diluted share, and announced a lease agreement for MGM Northfield Park with an affiliate of Clairvest.
Net income attributable to common stockholders rose 4.0% to $762.0 million, or $0.71 per share, though a $11.5 million change in the CECL allowance partly offset the increase.
AFFO per share rose 5.3% to $0.60 for the quarter, and the quarterly dividend was set at $0.45 per share, a 4.0% increase.
Full-year 2025 AFFO guidance was updated to $2,510 million to $2,520 million, compared with prior guidance of $2,500 million to $2,520 million.
The Northfield Park lease carries an initial annual base rent of $53.0 million, or $54.0 million if closing occurs on or after May 1, 2026, and is expected to close in the first half of 2026.
AMETEK reported third quarter 2025 sales of $1.89 billion, up 11% from a year earlier, and adjusted earnings of $1.89 per diluted share, up 14%. The company raised its full-year 2025 adjusted earnings per share guidance to $7.32 to $7.37 from $7.06 to $7.20, which matters to shareholders because it signals higher expected profit for the year.
Q3 2025 GAAP diluted EPS was $1.60, up from $1.47 in Q3 2024; adjusted EPS was $1.89, up from $1.66.
2025 adjusted EPS guidance raised to $7.32 to $7.37 from $7.06 to $7.20; overall sales still expected up mid-single digits versus 2024.
Q4 2025 adjusted EPS expected at $1.90 to $1.95, and overall sales expected up about 10% versus Q4 2024.
Acquisition-related pre-tax costs of $19.7 million ($0.07 per diluted share) were tied to the FARO Technologies acquisition in Q3.
IDACORP reported third quarter 2025 net income of $124.4 million, or $2.26 per diluted share, up from $113.6 million, or $2.12 per diluted share, a year earlier. The company raised its full-year 2025 earnings guidance to $5.80 to $5.90 per diluted share from $5.70 to $5.85, and said it reached a constructive settlement of its Idaho general rate case, which is pending approval by the Idaho Public Utilities Commission.
Q3 2025 net income attributable to IDACORP was $124.4 million, or $2.26 per diluted share, versus $113.6 million, or $2.12, in Q3 2024.
Nine-month 2025 net income was $279.9 million, or $5.13 per diluted share, versus $251.3 million, or $4.82, in the same period of 2024.
Full-year 2025 EPS guidance rose to $5.80 to $5.90 from $5.70 to $5.85, assuming normal weather and power supply expenses for the rest of 2025.
Idaho general rate case settlement is pending approval by the Idaho Public Utilities Commission.
APi Group reported third-quarter 2025 net revenues of $2.1 billion, up 14.2% from a year earlier, and net income of $93 million, up 34.8%. The company raised its full-year 2025 guidance for net revenues and adjusted EBITDA, which signals higher expected results for shareholders.
Q3 2025 net revenues were $2,085 million, up 14.2% (9.7% organic), versus $1,826 million a year earlier
Q3 net income was $93 million and diluted EPS was $0.20, compared with $69 million and $0.15 in Q3 2024
Full-year 2025 net revenue guidance raised to $7,825 to $7,925 million from $7,650 to $7,850 million
Full-year 2025 adjusted EBITDA guidance set at $1,015 to $1,045 million, up from $1,005 to $1,045 million
Cushman & Wakefield reported third-quarter 2025 revenue of $2.6 billion, up 11% from a year earlier, and net income of $51.4 million, compared with $33.7 million. It raised its full-year 2025 adjusted EPS growth guidance to 30%-35%, up from 25%-35%, and prepaid an additional $100 million of term loan debt on October 29, 2025. Equity method earnings fell $20.7 million, mainly due to a $46.1 million non-cash loan loss provision at the Greystone JV, of which the company recorded $18.5 million.
Q3 2025 revenue of $2.6 billion rose 11%; service line fee revenue of $1.8 billion rose 9%
Diluted EPS was $0.22 versus $0.14; adjusted diluted EPS was $0.29 versus $0.23
Full-year 2025 adjusted EPS growth guidance raised to 30%-35% from 25%-35%
Prepaid $100 million on October 29, 2025, bringing 2025 year-to-date prepayments to $300 million
L3Harris reported third-quarter 2025 revenue of $5.7 billion, up 7% from a year earlier, and GAAP diluted EPS of $2.46, up 17%. The company raised its 2025 guidance, lifting non-GAAP diluted EPS to $10.50-$10.70 from $10.40-$10.60 and revenue to about $22 billion from about $21.75 billion. Cash from operations fell 30% to $546 million, which the company attributed to temporary customer payment delays.
Third-quarter revenue $5.659 billion, up 7% (10% organic); GAAP operating margin 11.0% vs 9.4%
Non-GAAP diluted EPS $2.70, up 10%; GAAP diluted EPS $2.46, up from $2.10
2025 non-GAAP diluted EPS guidance raised to $10.50-$10.70; revenue guidance raised to about $22 billion
Cash from operations $546 million, down 30%; adjusted free cash flow $449 million, down 38%
DT Midstream reported third quarter 2025 net income of $115 million, or $1.13 per diluted share, and Adjusted EBITDA of $288 million. The company raised its 2025 Adjusted EBITDA guidance to $1,115 million to $1,145 million and declared a quarterly dividend of $0.82 per share, which matters to shareholders because it reflects higher expected earnings and a continued dividend payout.
Q3 2025 net income was $115 million, or $1.13 per diluted share, up from $107 million, or $1.04 per share, in Q2 2025
Adjusted EBITDA was $288 million for Q3 2025, compared with $277 million in Q2 2025
2025 Adjusted EBITDA guidance raised to $1,115 million to $1,145 million; 2026 early outlook reaffirmed at $1,155 million to $1,225 million
Quarterly dividend of $0.82 per share, payable January 15, 2026 to holders of record on December 15, 2025
CMS Energy reported third-quarter 2025 diluted EPS of $0.92, up from $0.84 a year earlier, and adjusted EPS of $0.93 versus $0.84. The company raised its 2025 adjusted EPS guidance to $3.56 to $3.60 from $3.54 to $3.60 and initiated 2026 adjusted EPS guidance of $3.80 to $3.87, which gives shareholders updated earnings expectations for both years.
Q3 2025 operating revenue was $2,021 million, compared with $1,743 million in Q3 2024; net income available to common stockholders was $275 million, compared with $251 million.
Year-to-date adjusted EPS was $2.66, compared with $2.47 a year earlier, which the company attributed largely to constructive regulatory outcomes and favorable weather.
The company reaffirmed long-term adjusted EPS growth of 6% to 8%, with continued confidence toward the high end, and will host a webcast on October 30 at 9:30 a.m. ET.
Vontier reported third-quarter 2025 sales of $752.5 million, up 0.3% from a year earlier, with GAAP diluted EPS of $0.70 versus $0.60 and adjusted diluted EPS of $0.78 versus $0.73. The company raised its full-year 2025 adjusted diluted EPS guidance to $3.15 to $3.20 and set a fourth-quarter range of $0.82 to $0.86, though Repair Solutions sales fell 6.9%.
Q3 2025 sales were $752.5 million, up 0.3%; core sales were flat year over year
GAAP diluted EPS was $0.70 vs. $0.60 a year earlier; adjusted diluted EPS was $0.78 vs. $0.73
Full-year 2025 adjusted diluted EPS guidance raised to $3.15 to $3.20; Q4 2025 guidance is $0.82 to $0.86
Repair Solutions sales declined 6.9% to $141.6 million; company repurchased about $175 million of shares year-to-date
Amneal reported third-quarter 2025 net revenue of $785 million, up 12% from $702 million a year earlier, and GAAP net income attributable to the company of $2 million, or $0.01 per diluted share, compared with a loss in the prior-year quarter. The company raised its 2025 adjusted EBITDA, adjusted diluted EPS and operating cash flow guidance and left net revenue guidance unchanged, while a $31.4 million loss on refinancing weighed on quarterly results.
Net revenue was $785 million, up 12%; Specialty rose 8%, Affordable Medicines rose 8% and AvKARE rose 24%.
GAAP net income attributable to Amneal was $2 million ($0.01 per diluted share); adjusted diluted EPS was $0.17, up 6% from $0.16.
2025 adjusted diluted EPS guidance was raised to $0.75-$0.80 from $0.70-$0.75, and adjusted EBITDA guidance to $675-$685 million from $665-$685 million.
The quarter included a $31.4 million loss on refinancing tied to the August 1, 2025 borrowing of $2.1 billion in term loans and $600 million of senior notes due 2032.
WESCO International reported third-quarter 2025 net sales of $6.2 billion, up 12.9% from a year earlier, and raised its full-year 2025 outlook for organic sales growth and adjusted EPS. Reported diluted EPS was $3.79, down 0.5%, and the company reduced its full-year free cash flow outlook because of higher working capital.
Q3 net sales of $6.2 billion, up 12.9%; organic sales up 12.1%; data center sales of $1.2 billion, up about 60%
Adjusted diluted EPS of $3.92, up 9.5%; GAAP diluted EPS of $3.79 versus $3.81, down 0.5%
Full-year organic sales growth outlook raised to 8% to 9% from 5% to 7%; adjusted EPS outlook set at $13.10 to $13.60
Full-year free cash flow outlook reduced; Q3 free cash flow was negative $89.3 million
Essex Property Trust reported third-quarter 2025 Core FFO of $3.97 per diluted share, up 1.5% from $3.91 a year earlier and $0.03 above the midpoint of its guidance range. Net income per diluted share rose to $2.56 from $1.84, mainly due to gains on sale of real estate, and the company raised its full-year 2025 Core FFO and net income guidance midpoints.
Q3 2025 Core FFO per diluted share $3.97 vs. $3.91 in Q3 2024; nine-month Core FFO $11.96 vs. $11.68
Q3 2025 net income per diluted share $2.56 vs. $1.84; nine-month Total FFO per share $12.03 vs. $12.30, down 2.2%
Full-year 2025 Core FFO guidance raised $0.03 at midpoint to $15.89 to $15.99; net income guidance raised $0.41 at midpoint to $10.53 to $10.63
Q3 2025 same-property revenue grew 2.7% and NOI grew 2.4% year over year; earnings call set for October 30, 2025 at 11 a.m. PT
Ventas reported third-quarter 2025 results with normalized FFO of $0.88 per share, up 10% from $0.80 a year earlier, and net income attributable to common stockholders of $66.0 million, versus $19.2 million in the prior-year quarter. The company raised its full-year 2025 guidance for normalized FFO per share to a range of $3.45 to $3.48 from $3.41 to $3.46, and lifted its senior housing investment volume expectation to $2.5 billion from $2.0 billion.
Q3 2025 total revenues were $1.49 billion, up from $1.24 billion in Q3 2024.
Q3 2025 same-store cash NOI for the senior housing operating portfolio (SHOP) grew 16% year over year, with same-store cash NOI margin up 200 basis points.
Full-year 2025 normalized FFO per share guidance midpoint rose to $3.47 from $3.44 as of July 30, 2025.
Net debt to further adjusted EBITDA improved to 5.3x at September 30, 2025, a 1.0x improvement from Q3 2024.
Encompass Health reported third-quarter 2025 net operating revenue of $1,477.5 million, up 9.4% from a year earlier, and adjusted earnings per share of $1.23, up from $1.03. The company raised its full-year 2025 guidance for adjusted EBITDA and adjusted EPS, and its revenue range was narrowed. Adjusted free cash flow fell 8.2% in the quarter, to $174.2 million.
Q3 2025 diluted EPS from continuing operations was $1.24, up from $1.07; adjusted EPS was $1.23, up from $1.03.
Q3 adjusted EBITDA was $300.1 million, up 11.4% from $269.3 million; adjusted free cash flow was $174.2 million, down from $189.7 million.
Full-year 2025 adjusted EPS guidance rose to $5.22 to $5.37 from $5.12 to $5.34; adjusted EBITDA guidance rose to $1,235 million to $1,255 million from $1,220 million to $1,250 million.
Full-year 2025 net operating revenue guidance was narrowed to $5,905 million to $5,955 million from $5,880 million to $5,980 million.
Rush Street Interactive reported third-quarter 2025 revenue of $277.9 million, up 20% from a year earlier, and net income of $14.8 million, up from $3.2 million. It also raised its full-year 2025 revenue and Adjusted EBITDA guidance, which matters to shareholders because it signals higher expected results for the year.
Q3 revenue was $277.9 million, up 20% from $232.1 million in Q3 2024.
Q3 net income was $14.8 million versus $3.2 million; diluted EPS was $0.06 versus $0.01.
Adjusted EBITDA was $36.0 million, up 54% from $23.4 million.
2025 revenue guidance was raised to $1.1 billion to $1.12 billion, and Adjusted EBITDA guidance to $147 million to $153 million.
American Homes 4 Rent (AMH) reported third quarter 2025 results on October 29, 2025, with rents and other single-family property revenues up 7.5% year-over-year to $478.5 million and net income attributable to common shareholders of $99.7 million, or $0.27 per diluted share, versus $0.20 a year earlier. The company raised the midpoint of its full year 2025 Core FFO guidance by $0.01 per share to $1.87, which matters to shareholders because it signals higher expected per-share operating earnings for the year.
Q3 2025 rents and other single-family property revenues rose 7.5% to $478.5 million, from $445.1 million in Q3 2024.
Net income attributable to common shareholders was $99.7 million, or $0.27 per diluted share, versus $73.8 million, or $0.20, in Q3 2024.
Core FFO was $0.47 per share and unit, up 6.2% year-over-year; Adjusted FFO was $0.42, up 9.1%.
Full year 2025 Core FFO guidance is now $1.86 to $1.88 per share, up from $1.84 to $1.88, with the midpoint raised to $1.87.
Waystar reported third-quarter 2025 revenue of $268.7 million, up 12% year over year, and net income of $30.6 million, or $0.17 per diluted share, compared with $5.4 million, or $0.03, a year earlier. The company also raised its full-year 2025 revenue and adjusted EBITDA guidance, which signals management's confidence in the rest of the year.
Q3 revenue was $268.7 million, up from $240.1 million in Q3 2024.
Q3 net income was $30.6 million, or $0.17 per diluted share, versus $5.4 million, or $0.03, a year earlier.
Full-year 2025 revenue guidance is $1.085 billion to $1.093 billion, and adjusted EBITDA guidance is $451 million to $455 million, both raised.
Q3 non-GAAP net income was $67.8 million, or $0.37 per diluted share.
Vita Coco reported third-quarter 2025 results on October 29, 2025, with net sales up 37% to $182 million and net income of $24 million, or $0.40 per diluted share, compared with $19 million and $0.32 a year earlier. The company raised its full-year 2025 net sales guidance to $580 million to $595 million and its adjusted EBITDA guidance to $90 million to $95 million, although gross margin fell to 38% from 39%.
Q3 net sales were $182 million, up 37%, with Vita Coco Coconut Water net sales up 42%.
Q3 net income was $24 million ($0.40 diluted EPS) versus $19 million ($0.32); adjusted EBITDA was $32 million versus $23 million.
Full-year 2025 guidance: net sales of $580 million to $595 million and adjusted EBITDA of $90 million to $95 million.
Gross margin was 38% versus 39%, reflecting higher finished goods and tariff costs; the company reported no debt and $204 million in cash as of September 30, 2025.
Fortive reported third-quarter 2025 revenue of $1.03 billion, up 2.3% year over year, with adjusted diluted EPS of $0.68, up 15.3%. The company raised its full-year 2025 adjusted diluted EPS guidance to $2.63 to $2.67 from $2.50 to $2.60, and executed $1 billion of share repurchases, about 6% of diluted shares outstanding. Operating cash flow and free cash flow declined in the quarter, and the GAAP net earnings figure of $55 million reflects a $62 million loss from discontinued operations.
Q3 2025 revenue was $1.03 billion, up 2.3%; core revenue rose 1.9%
GAAP diluted EPS was $0.35, up 9.4%; adjusted diluted EPS was $0.68, up 15.3%
Full-year 2025 adjusted diluted EPS guidance raised to $2.63 to $2.67 from $2.50 to $2.60
Share repurchases totaled $1 billion, comprising 21 million shares
Dana reported third-quarter 2025 sales of $1.92 billion from continuing operations, up from $1.90 billion a year earlier, and net income of $13 million compared with a net loss of $21 million. The company raised its full-year profit guidance, citing accelerated cost savings, and said the Off-Highway divestiture remains on track to close in late 2025.
Q3 adjusted EBITDA was $162 million, or 8.5 percent of sales, compared with $111 million, or 5.9 percent, a year earlier
Full-year 2025 adjusted EBITDA guidance for continuing operations is $570 million to $610 million; sales guidance is $7.3 billion to $7.5 billion
Dana repurchased $189 million of shares in Q3 and expects to repurchase $155 million more in Q4, bringing the 2025 total to $600 million
Cost savings were $73 million in Q3 and $183 million year to date, with $235 million expected for 2025
Urban Edge Properties reported third-quarter 2025 net income attributable to common shareholders of $14.9 million, up from $9.1 million a year earlier, and raised its full-year 2025 guidance. The company also said it acquired Brighton Mills Shopping Center in Massachusetts for $39 million, adding to its Boston-area holdings.
Q3 2025 net income attributable to common shareholders was $14,935 thousand, or $0.12 per diluted share, versus $9,080 thousand, or $0.07, in Q3 2024.
Q3 2025 FFO as Adjusted per diluted share was $0.36, compared with $0.35 a year earlier.
2025 FFO as Adjusted guidance is now $1.42 to $1.44 per diluted share, with a midpoint of $1.43, up from $1.42.
On October 23, 2025, the company acquired Brighton Mills Shopping Center for a gross purchase price of $39 million.
Otis reported third quarter 2025 net sales of $3.7 billion, up 4%, with organic sales up 2%. Service sales rose 9%, while New Equipment sales fell 4%, and the company raised the midpoint of its 2025 adjusted EPS outlook to $4.04 to $4.08. GAAP EPS fell 29% to $0.95 because of a non-recurring tax benefit in the prior-year quarter, but adjusted EPS rose 9% to $1.05.
Q3 2025 net sales of $3.7 billion, up 4%; organic sales up 2%
Q3 adjusted EPS of $1.05, up 9%; GAAP EPS of $0.95, down 29%
2025 adjusted EPS outlook of $4.04 to $4.08, up 5 to 7%, with the midpoint raised
Q3 Service net sales up 9%; New Equipment net sales down 4%, with China down about 20%
Jack Henry & Associates reported $8.6 million of deconversion revenue for the fiscal first quarter ended September 30, 2025, and raised its full-year fiscal 2026 deconversion revenue estimate to $20 million. The filing covers only this revenue line, not total revenue or earnings, and the company says deconversion revenue is excluded from its non-GAAP revenue because it mainly arises when a client is acquired by another institution.
Fiscal Q1 2026 (quarter ended September 30, 2025) deconversion revenue was $8.6 million.
Full-year fiscal 2026 deconversion revenue estimate increased to $20 million.
Most deconversion revenue comes from clients being acquired by another financial institution, which ends their contract with Jack Henry.
Deconversion revenue is excluded from non-GAAP revenue in quarterly and annual earnings releases.
BrightSpring Health Services reported third-quarter 2025 revenue of $3,334 million, up 28.2% from a year earlier, and Adjusted EBITDA of $160 million, up 37.2%. The company raised its full-year 2025 revenue guidance and reiterated its Adjusted EBITDA guidance, which matters to shareholders because the headline sales and profit measures both improved.
Q3 2025 revenue was $3,334 million, up 28.2% from $2,601 million; continuing-operations net income was $37.5 million versus a net loss of $25.7 million a year earlier.
Adjusted EBITDA was $160 million, up 37.2% from $117 million.
2025 revenue guidance was raised to $12,500 million to $12,800 million; Adjusted EBITDA guidance of $605 million to $615 million was reiterated.
The planned sale of the Community Living business to Sevita is expected to close in Q1 2026.
W. P. Carey reported third-quarter 2025 revenues of $431.3 million, up 8.5% from a year earlier, and net income attributable to the company of $141.0 million, up 26.2%. The company raised and narrowed its full-year 2025 AFFO guidance to $4.93 to $4.99 per diluted share, citing higher expected investment volume, which matters to shareholders because AFFO is the company's main per-share earnings measure.
Q3 2025 revenues of $431.3 million, up 8.5% from $397.4 million in Q3 2024
Diluted EPS of $0.64 versus $0.51; AFFO of $1.25 per diluted share versus $1.18
2025 AFFO guidance raised and narrowed to $4.93 to $4.99 per diluted share, based on investment volume of $1.8 billion to $2.1 billion
Quarterly cash dividend of $0.910 per share, a 4.0% increase over the 2024 third quarter
EXL reported third-quarter 2025 results, with revenue up 12.2% year over year to $529.6 million and GAAP diluted EPS up 10.7% to $0.36. The company raised its full-year 2025 guidance for both revenue and adjusted diluted EPS, which points to stronger expected growth for shareholders, though operating income margin slipped to 14.4% from 14.7% a year earlier.
Q3 revenue of $529.6 million, up from $472.1 million in Q3 2024 (12.2% reported growth)
GAAP diluted EPS of $0.36 vs. $0.33 a year earlier; adjusted diluted EPS of $0.48 vs. $0.44
2025 revenue guidance raised to $2.07 billion to $2.08 billion; adjusted diluted EPS guidance raised to $1.88 to $1.92
Operating income margin of 14.4%, down from 14.7% in Q3 2024; conference call set for October 29, 2025 at 10:00 A.M. ET
Universal Health Services reported third-quarter 2025 net revenues up 13.4% to $4.495 billion and diluted EPS of $5.86, versus $3.80 a year earlier, and raised its full-year 2025 forecast for net revenues, Adjusted EBITDA net of NCI and Adjusted EPS-diluted. The board also added $1.5 billion to the stock repurchase authorization, bringing the available total to $1.759 billion, which matters to shareholders because it raises both the earnings outlook and the capacity for share buybacks.
Q3 2025 net income attributable to UHS was $373.0 million, or $5.86 per diluted share, versus $258.7 million, or $3.80, in Q3 2024
Q3 results included $90 million of pre-tax Medicaid reimbursements for Washington, D.C. and a $35 million pre-tax charge for professional and general liability reserves
2025 Adjusted EPS-diluted forecast raised to $21.50-$22.10 from $20.00-$21.00; net revenues forecast raised to $17.306-$17.445 billion
Board authorized a $1.5 billion increase to the stock repurchase program on October 27, 2025; 1.315 million shares repurchased in Q3 2025 for about $234.3 million
Repligen reported third-quarter 2025 revenue of $189 million, up 22% from $155 million a year earlier, and GAAP net income of $15 million versus a $1 million loss in the prior-year quarter. The company raised its full-year 2025 revenue guidance to $729 million to $737 million, and GAAP diluted EPS guidance is $0.82 to $0.85.
Q3 2025 revenue was $189 million, up 22% as reported and 18% organic, with no COVID-related revenue in either period.
GAAP diluted EPS was $0.26 versus a loss of $0.01 a year earlier; adjusted diluted EPS was $0.46 versus $0.43.
Full-year 2025 revenue guidance was increased to $729 million to $737 million, with GAAP diluted EPS guidance of $0.82 to $0.85.
Cash and cash equivalents were $749 million at September 30, 2025, compared with $757 million at December 31, 2024.
Incyte reported third-quarter 2025 total revenues of $1.37 billion, up 20% from a year earlier, and GAAP net income of $424.2 million, or $2.11 per diluted share, compared with $106.5 million, or $0.54 per diluted share, in the prior-year quarter. The company raised its full-year 2025 net product revenue guidance to $4.23-$4.32 billion, while reiterating its guidance for cost of product revenues, R&D and SG&A expenses.
Total revenues were $1.37 billion, up 20%; total net product revenues were $1.15 billion, up 19%.
GAAP diluted EPS was $2.11 versus $0.54 a year earlier; GAAP net income was $424.2 million versus $106.5 million.
Jakafi net product revenue rose 7% to $791 million; Opzelura rose 35% to $188 million.
Full-year 2025 net product revenue guidance was raised to $4.23-$4.32 billion, from the prior range that the filing lists for Jakafi and other oncology products.
Crane Company reported third quarter 2025 GAAP EPS from continuing operations of $1.56, up 25%, and adjusted EPS of $1.64, up 27%, on sales of $589.2 million, up 7.5%. The company raised and narrowed its full-year adjusted EPS outlook to $5.75-$5.95 from $5.50-$5.80, which management said reflects 20% growth at the midpoint over 2024.
Q3 2025 GAAP EPS from continuing operations was $1.56 versus $1.25 a year earlier; adjusted EPS was $1.64 versus $1.29.
Net sales were $589.2 million, up 7.5%, including 5.6% core sales growth; backlog was $1,437.1 million at September 30, 2025.
Full-year adjusted EPS outlook raised to $5.75-$5.95 from $5.50-$5.80; the company declared a fourth quarter dividend of $0.23 per share.
Keurig Dr Pepper reported third-quarter 2025 net sales of $4.3 billion, up 10.7% from a year earlier, and GAAP diluted EPS of $0.49, up 8.9%. The company raised its full-year 2025 constant currency net sales growth outlook to a high-single-digit range from mid-single-digit, and reaffirmed its adjusted EPS growth outlook of high-single-digit.
Q3 2025 net sales were $4.3 billion, up 10.7%; constant currency net sales rose 10.6%
GAAP diluted EPS was $0.49, up 8.9%; adjusted diluted EPS was $0.54, up 5.9%
Full-year 2025 constant currency net sales growth outlook raised to high-single-digit from mid-single-digit
Adjusted diluted EPS growth outlook of high-single-digit reaffirmed
HCA Healthcare reported third-quarter 2025 revenue of $19.161 billion, up 9.6%, and net income attributable to HCA of $1.643 billion, or $6.96 per diluted share, compared with $4.88 a year earlier. The company raised its 2025 diluted EPS guidance to $27.00 to $28.00 per share, from $25.50 to $27.00, and declared a $0.72 quarterly dividend.
Q3 2025 revenue was $19.161 billion, up from $17.487 billion; diluted EPS was $6.96 versus $4.88.
Revised 2025 diluted EPS guidance is $27.00 to $28.00, up from $25.50 to $27.00 set on July 25, 2025.
Revised 2025 Adjusted EBITDA guidance is $15.250 billion to $15.650 billion, up from $14.700 billion to $15.300 billion.
Quarterly dividend of $0.72 per share is payable December 29, 2025, to holders of record on December 15, 2025.
Digital Realty reported third-quarter 2025 results on October 23, 2025, with revenue of $1.6 billion, up 10% from a year earlier, and Core FFO of $1.89 per diluted share, up from $1.67. The company raised its 2025 Core FFO per share outlook to $7.32-$7.38 from $7.15-$7.25, which signals higher expected cash earnings for shareholders this year.
Q3 2025 revenue of $1.6 billion, up 10% from the same quarter last year; net income available to common stockholders was $0.15 per diluted share, compared with $0.09 a year earlier.
Core FFO per diluted share of $1.89 versus $1.67 in Q3 2024; FFO per share of $1.65 versus $1.55.
2025 Core FFO per share outlook raised to $7.32-$7.38, up from $7.15-$7.25 in the July 24, 2025 outlook; total revenue outlook raised to $6.025-$6.075 billion.
Signed bookings expected to generate $201 million of annualized GAAP rental revenue at 100% share; backlog of signed-but-not-commenced leases was $852 million at quarter-end.
Harmony Biosciences said preliminary third-quarter 2025 net revenue for the WAKIX franchise was about $239 million, up 29% year over year, and raised its 2025 revenue guidance to $845 million-$865 million from $820 million-$860 million. The figures are preliminary and unaudited, and the company will report full third-quarter results on November 4, 2025.
WAKIX franchise net revenue of about $239 million in Q3 2025, up 29% year over year
Average patients reached 8,100 in Q3 2025, an increase of about 500 for the quarter
2025 revenue guidance raised to $845 million-$865 million from $820 million-$860 million
Results are preliminary and unaudited; full Q3 2025 results and conference call set for November 4, 2025
West Pharmaceutical Services reported third-quarter 2025 net sales of $804.6 million, up 7.7% from a year earlier, and diluted EPS of $1.92 versus $1.85. The company raised its full-year 2025 net sales guidance to $3.060 billion to $3.070 billion and adjusted-diluted EPS guidance to $7.06 to $7.11, and it introduced fourth-quarter guidance that is below the third-quarter level.
Q3 net sales $804.6 million (up 7.7%, organic up 5.0%); HVP Components rose 16.3% to $390.0 million
Q3 diluted EPS $1.92 vs. $1.85; adjusted-diluted EPS $1.96 vs. $1.85 a year earlier
Full-year 2025 adjusted-diluted EPS guidance raised to $7.06 to $7.11, from $6.65 to $6.85
Fourth-quarter 2025 net sales guidance of $790 million to $800 million and adjusted-diluted EPS guidance of $1.81 to $1.86
CBRE Group reported third-quarter 2025 results, with revenue up 14% to $10.3 billion and GAAP EPS up 66% to $1.21. The company raised its 2025 Core EPS outlook to $6.25 to $6.35 from $6.10 to $6.20, which points to higher expected profit for shareholders this year.
Q3 GAAP EPS $1.21 vs. $0.73 a year earlier; Core EPS $1.61, up 34%
Revenue $10.3 billion, up 14%; GAAP net income $363 million, up 61%
2025 Core EPS outlook raised to $6.25 to $6.35 from $6.10 to $6.20
Repurchased about 5.2 million shares for $663 million since year-end 2024; about $5.2 billion of authorization remained as of September 30, 2025
Getty Realty reported third quarter 2025 net earnings of $0.40 per diluted share, up from $0.27 a year earlier, and raised its full-year 2025 AFFO per share guidance to $2.42 to $2.43 from $2.40 to $2.41. The company attributed the increase to year-to-date investment activity, which totaled $236.8 million at a 7.9% initial cash yield.
Q3 2025 net earnings were $23.3 million, or $0.40 per diluted share, versus $15.3 million, or $0.27, in Q3 2024.
Q3 2025 AFFO was $0.62 per diluted share, up from $0.59; FFO was $0.66, up from $0.56.
2025 AFFO guidance raised to $2.42 to $2.43 per diluted share from $2.40 to $2.41.
Committed investment pipeline of more than $75.0 million for 22 properties as of October 22, 2025.
FirstEnergy reported third-quarter 2025 GAAP earnings of $441 million, or $0.76 per share, on revenue of $4.1 billion, up from $419 million and $3.7 billion a year earlier. The company narrowed its 2025 Core EPS guidance to $2.50 to $2.56 per share, within the upper half of its original $2.40 to $2.60 range, and raised its 2025 capital investment plan to $5.5 billion, while affirming a 6-8% annual Core Earnings growth target through 2029.
Q3 2025 Core EPS was $0.83, up 9% from $0.76 in Q3 2024; year-to-date Core EPS was $2.02, up 15% from $1.76.
2025 Core EPS guidance narrowed to $2.50 to $2.56 per share, versus the original $2.40 to $2.60 range.
2025 capital investment plan increased 10%, from $5.0 billion to $5.5 billion.
Company affirmed a 6-8% compounded annual Core Earnings growth rate target for 2025 through 2029.
Essential Properties Realty Trust reported third quarter 2025 results on October 22, 2025, with diluted net income per share of $0.33, up from $0.27 a year earlier, and AFFO per share of $0.48, up 12%. The company raised its 2025 AFFO per share guidance to $1.87 to $1.89 and issued 2026 guidance of $1.98 to $2.04 per share, which affects shareholders' expectations for future cash earnings.
Q3 2025 total revenues were $144.9 million, up from $117.1 million in Q3 2024
Closed $369.8 million of investments across 87 properties at an 8.0% weighted average cash cap rate
2025 AFFO per share guidance raised to $1.87 to $1.89, with 2026 AFFO guidance of $1.98 to $2.04
Quarterly dividend of $0.30 per share was paid October 14, 2025; management will hold a conference call October 23, 2025 at 10:00 a.m. ET
Wabtec reported third quarter 2025 sales of $2.89 billion, up 8.4%, with GAAP diluted EPS of $1.81 (up 11.0%) and adjusted diluted EPS of $2.32 (up 16.0%). The company raised its 2025 adjusted EPS guidance to $8.85 to $9.05, up $0.10 at the midpoint, while its full-year revenue outlook of $10.925 billion to $11.225 billion was unchanged. Cash from operations fell to $367 million from $542 million, which the company partly attributed to higher tariffs and working capital.
Q3 2025 sales were $2.89 billion, up 8.4%; GAAP EPS was $1.81 and adjusted EPS was $2.32.
2025 adjusted EPS guidance was raised and tightened to $8.85 to $9.05, up $0.10 at the midpoint.
Full-year 2025 revenue guidance of $10.925 billion to $11.225 billion was continued, not changed.
Q3 cash from operations was $367 million versus $542 million a year earlier; 12-month backlog rose 8.4% to $8,267 million.
Matador Resources reported third-quarter 2025 net income of $176 million, or $1.42 per share, and record production of 209,184 barrels of oil equivalent per day. The company raised its full-year 2025 production and drilling capital guidance and declared a higher quarterly dividend of $0.375 per share.
Q3 2025 net income of $176 million, or $1.42 per diluted share; adjusted EPS of $1.36
Q3 2025 production of 209,184 BOE per day, a Company record and a 22% year-over-year increase
Full-year 2025 production guidance raised to 205,500 to 206,500 BOE per day from 200,000 to 205,000
Full-year 2025 D/C/E capital expenditure guidance raised to $1.47 billion to $1.55 billion from $1.18 billion to $1.37 billion
Agree Realty reported third-quarter 2025 results on October 21, 2025. Net income attributable to common stockholders rose 18.2% to $50.3 million, and AFFO per share rose 7.2% to $1.10. The company raised its 2025 AFFO per share guidance to $4.31 to $4.33 and its 2025 investment volume guidance to $1.50 billion to $1.65 billion, which signals higher expected earnings and growth for shareholders.
Q3 net income attributable to common stockholders was $50.3 million, up 18.2%; $0.45 per share, up 7.9%
Q3 Core FFO per share was $1.09, up 8.4%; AFFO per share was $1.10, up 7.2%
2025 AFFO per share guidance raised to $4.31 to $4.33 from $4.29 to $4.32
Q3 investment volume was about $451 million in 110 properties; 2025 investment guidance raised to $1.50 billion to $1.65 billion
Valmont reported third-quarter 2025 net sales up 2.5% to $1.05 billion and diluted EPS up 21.2% to $4.98 versus the prior-year quarter. The company raised its full-year 2025 adjusted diluted EPS outlook to $18.70 to $19.50 from $17.50 to $19.50, but nine-month GAAP diluted EPS fell 41.5% to $7.80 after a $91.3 million impairment of long-lived assets earlier in the year.
Q3 net sales rose 2.5% to $1.05 billion; operating income rose 12.5% to $141.5 million
Q3 diluted EPS rose 21.2% to $4.98 from $4.11
Full-year 2025 adjusted diluted EPS outlook raised to $18.70 to $19.50 from $17.50 to $19.50
Nine-month GAAP diluted EPS fell 41.5% to $7.80, including a $91.3 million impairment of long-lived assets
BrightSpring Health Services reported preliminary third-quarter 2025 results for continuing operations, with revenue of approximately $3,334 million, up 28.2%, and Adjusted EBITDA of approximately $160 million, up 37.2%. The company raised its full-year 2025 revenue and Adjusted EBITDA guidance, which excludes the pending Community Living divestiture to Sevita. The results are preliminary, and full third-quarter results will be announced on October 28, 2025.
Q3 2025 revenue of approximately $3,334 million, up 28.2% from approximately $2,601 million; Adjusted EBITDA of approximately $160 million, up 37.2% from approximately $117 million.
Q3 2025 net income of approximately $37.5 million, compared with a net loss of approximately $25.7 million in Q3 2024.
2025 revenue guidance raised to $12,400 million to $12,700 million; Adjusted EBITDA guidance raised to $605 million to $615 million.
Community Living divestiture to Sevita is expected to close in early Q1 2026; full Q3 results and conference call on October 28, 2025.
On October 15, 2025, HPE hosted its Securities Analyst Meeting and gave fiscal 2026 guidance, including revenue growth of 5% to 10% and non-GAAP diluted EPS of $2.20 to $2.40. The board approved a $3 billion increase to the share repurchase program, which has no expiration date, and the company announced a 10% increase to its annual dividend, subject to board approval. The filing also reorganizes segments into Cloud & AI, Networking, and Corporate Investments and Other starting in fiscal 2026, and HPE estimates Juniper-related workforce reductions will cost approximately $240 million.
Fiscal 2026 guidance: revenue growth of 5% to 10%, non-GAAP diluted EPS of $2.20 to $2.40, GAAP diluted EPS of $0.57 to $0.77, and free cash flow of $1.5 billion to $2.0 billion
Share repurchase authorization increased by $3 billion to approximately $3.7 billion in total, with no expiration date
Annual dividend to increase 10% for fiscal 2026, subject to board approval
Juniper integration workforce reductions estimated to cost approximately $240 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.